Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer

Overexpression of breast cancer resistance protein (BCRP) has been shown to produce multidrug resistance (MDR) in colon cancer, leading to major obstacles for chemotherapy. In this study, we evaluated the effect of regorafenib, an oral multi-kinase inhibitor, in inhibiting BCRP-mediated MDR in silic...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Lett
Autori principali: Zhang, Yun-Kai, Wang, Yi-Jun, Lei, Zi-Ning, Zhang, Guan-Nan, Zhang, Xiao-Yu, Wang, De-shen, Al-Rihani, Sweilem B., Shukla, Suneet, Ambudkar, Suresh V., Kaddoumi, Amal, Shi, Zhi, Chen, Zhe-Sheng
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8148022/
https://ncbi.nlm.nih.gov/pubmed/30392788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2018.10.032
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi